SR One funds disclose 8% Odyssey Therapeutics (ODTX) stake after IPO

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

SCHEDULE 13D

Rhea-AI Filing Summary

SR One-affiliated funds filed a Schedule 13D reporting beneficial ownership of 3,794,883 shares of Odyssey Therapeutics common stock, representing 8.0% of the company. The stake is held across SR One Fund I Aggregator, SR One Co-Invest vehicles and AMZL, all controlled through SR One Capital Management and ultimately by Dr. Simeon George.

The position arose from Odyssey’s initial public offering of 15,500,000 shares at $18.00 per share and the automatic conversion of multiple preferred stock series and warrants into common stock immediately before the IPO closing. The filing states the investment is for investment purposes, with no current plans for corporate changes.

The funds have registration rights under an Investors' Rights Agreement, including demand and piggyback rights, and are subject to a 180-day lock-up from May 7, 2026 that restricts sales, hedging and registration demands during that period.

Key Figures

SR One beneficial stake: 3,794,883 shares (8.0%) Shares outstanding: 47,174,156 shares IPO size: 15,500,000 shares +5 more

8 metrics

SR One beneficial stake 3,794,883 shares (8.0%) Odyssey Therapeutics common stock beneficially owned by SR One-affiliated funds

Shares outstanding 47,174,156 shares Odyssey Therapeutics common shares outstanding as of May 11, 2026

IPO size 15,500,000 shares Initial public offering of Odyssey Therapeutics common stock, excluding over-allotment option

IPO price $18.00 per share Price paid by SR One Fund I Aggregator, SR One Co-Invest IV-A and AMZL in the IPO

SR One Fund I Aggregator holding 1,831,383 shares Common stock held after preferred and warrant conversions plus IPO purchase

AMZL holding 1,014,851 shares Common stock held after Series C, Series D and warrant conversions plus IPO purchase

S-1 demand threshold $10 million Minimum anticipated aggregate offering amount for Form S-1 registration rights request

Lock-up period 180 days Duration after May 7, 2026 during which funds agree not to sell or hedge shares

Key Terms

Schedule 13D, beneficially own, Investors' Rights Agreement, registration rights, +2 more

6 terms

Schedule 13D regulatory

"This statement on (this "Statement") relates to the shares of common stock..."

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

beneficially own financial

"may be deemed to beneficially own the SR One Fund I Aggregator Shares"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

Investors' Rights Agreement regulatory

"Each Fund is party to the Third Amended and Restated Investors' Rights Agreement"

registration rights regulatory

"The Investors' Rights Agreement grants the parties thereto, including the Funds, certain registration rights"

Registration rights are contractual promises that let investors require a company to file paperwork with securities regulators so those investors can sell their shares to the public. They matter because they create a path to liquidity and an exit plan—without them, investors may be stuck holding shares for a long time. Think of them like a reserved ticket that guarantees access to a public marketplace when the holder is ready to sell.

lock-up agreement regulatory

"each Fund entered into a lock-up agreement in connection with the IPO"

A lock-up agreement is a contract that prevents company insiders and early investors from selling their shares for a fixed period after a stock sale, often after an initial public offering. It matters to investors because it temporarily limits the number of shares that can hit the market, which can keep the share price steadier; when the lock-up ends, a sudden increase in available shares can create extra volatility, revealing insiders’ confidence or lack thereof.

Rule 144 regulatory

"at such time that such holder can sell its shares under Rule 144 without limitation"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

05/18/2026 - 06:29 PM

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

Odyssey Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

67613T104

(CUSIP Number)

Sasha Keough
c/o SR One Capital Management, LP, 929 Main Street, Suite 200
Redwood City, CA, 94063
(410) 800-7503

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

05/11/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

Item 1.

Security and Issuer

(a)

Title of Class of Securities:

Common Stock, $0.0001 par value per share

(b)

Name of Issuer:

Odyssey Therapeutics, Inc.

(c)

Address of Issuer's Principal Executive Offices:

51 Sleeper Street, Suite 800, Boston, MASSACHUSETTS , 02210.

Item 1 Comment:

This statement on Schedule 13D (this "Statement") relates to the shares of common stock, $0.0001 par value per share ("Common Stock") of Odyssey Therapeutics, Inc. (the "Issuer").

Item 2.

Identity and Background

(a)

SR One Capital Management, LLC ("SR One Capital Management"); SR One Capital Fund I Aggregator, LP ("SR One Fund I Aggregator"); SR One Capital Partners I, LP ("SR One Partners I"); SR One Co-Invest IV, LLC ("SR One Co-Invest IV"); SR One Co-Invest IV-A, LLC ("SR One Co-Invest IV-A"); SR One Co-Invest IV Manager, LLC ("SR One Co-Invest IV Manager"); AMZL, LP ("AMZL"); SR One Capital SMA Partners, LP ("SMA Partners"); and Simeon George, M.D. ("Dr. George"). SR One Fund I Aggregator is directly controlled by its general partner, SR One Partners I. SR One Co-Invest IV and SR One Co-Invest IV-A are directly controlled by their managing members, SR One Co-Invest IV Manager. AMZL is directly controlled by its general partner, SMA Partners. SR One Partners I and SMA Partners are directly controlled by their general partners, SR One Capital Management, SR One Co-Invest IV Manager is directly controlled by its managing member, SR One Capital Management, and Dr. George controls SR One Capital Management. Accordingly, each of SR One Capital Management and Dr. George may be deemed to have voting and dispositive power with respect to the SR One Fund I Aggregator Shares, the SR One Co-Invest IV Shares, the SR One Co-Invest IV-A Shares and the AMZL Shares (each as defined below). The persons named in this Item 2 are referred to individually herein as a "Reporting Person" and collectively as the "Reporting Persons." SR One Fund I Aggregator, SR One Co-Invest IV, SR One Co-Invest IV-A and AMZL are referred to collectively as the "Funds."

(b)

The address of each Reporting Person for purposes of this filing is c/o SR One Capital Management, LP, 929 Main Street, Suite 200, Redwood City, CA 94063.

(c)

The principal business of the Funds is to invest in and assist growth-oriented businesses. The principal business of SR One Partners I is to act as the sole general partner of SR One Fund I Aggregator. The principal business of SR One Co-Invest Manager is to act as the managing member of SR One Co-Invest IV and SR One Co-Invest IV-A. The principal business of SMA Partners is to act as the general partner of AMZL. The principal business of SR One Capital Management is to act as the sole general partner of SR One Partners I and SMA Partners and the sole managing member of SR One Co-Invest IV Manager and a number of affiliated partnerships and limited liability companies with similar businesses. The principal business of Dr. George is to manage SR One Capital Management.

(d)

During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(e)

(f)

SR One Fund I Aggregator, SR One Partners I, AMZL, and SMA Partners are limited partnerships organized under the laws of the State of Delaware. SR One Co-Invest IV, SR One Co-Invest IV-A, SR One Co-Invest IV Manager and SR One Capital Management are limited liability companies organized under the laws of the State of Delaware. Dr. George is a United States citizen.

Item 3.

Source and Amount of Funds or Other Consideration

On May 7, 2026, the Registration Statement on Form S-1 filed with the Securities and Exchange Commission (the "SEC") by the Issuer (File No. 333-295141) in connection with its initial public offering of 15,500,000 shares of Common Stock of the Issuer (exclusive of the 2,325,000 shares of Common Stock that the underwriters may purchase upon exercise of their option to purchase additional shares in full) (the "IPO") was declared effective. The closing of the IPO took place on May 11, 2026 (the "Closing"), and in connection with the Closing, SR One Fund I Aggregator purchased 222,222 shares of Common Stock, SR One Co-Invest IV-A purchased 133,333 shares of Common Stock and AMZL purchased 200,000 shares of Common Stock, each at the IPO price of $18.00 per share. Prior to the Closing, SR One Fund I Aggregator purchased from the Issuer in a series of private transactions 4,606,320 shares of Series A Convertible Preferred Stock (the "SR One Fund I Aggregator Series A Preferred Stock") for an aggregate purchase price of $19,999,996.56; 1,299,842 shares of Series A-2 Convertible Preferred Stock (the "SR One Fund I Aggregator Series A-2 Preferred Stock") for an aggregate purchase price of $7,999,994.57; 544,162 shares of Series B Convertible Preferred Stock (the "SR One Fund I Aggregator Series B Preferred Stock") for an aggregate purchase price of $3,499,998.53; 600,142 shares of Series C Convertible Preferred Stock (the "SR One Fund I Aggregator Series C Preferred Stock") for an aggregate purchase price of $3,000,710.00; and 6,644,650 shares of Series D Convertible Preferred Stock (the "SR One Fund I Aggregator Series D Preferred Stock"), along with 1,861,211 warrants to purchase shares of Common Stock (the "SR One Fund I Aggregator Series D Warrants"), for an aggregate purchase price of $9,999,998.92. Immediately prior to the Closing, the SR One Fund I Aggregator Series A Preferred Stock automatically converted into 474,048 shares of Common Stock on a 1-for-9.7170 basis; the SR One Fund I Aggregator Series A-2 Preferred Stock automatically converted into 139,366 shares of Common Stock on a 1-for-9.3268 basis; the SR One Fund I Aggregator Series B Preferred Stock automatically converted into 59,692 shares of Common Stock on a 1-for-9.2837 basis; the SR One Fund I Aggregator Series C Preferred Stock automatically converted into 61,762 shares of Common Stock on a 1-for-9.7170 basis; the SR One Fund I Aggregator Series D Preferred Stock automatically converted into 683,817 shares of Common Stock on a 1-for-9.7170 basis; and the SR One Fund I Aggregator Series D Warrants were automatically exercised for 191,541 shares of Common Stock by their terms (as adjusted for the 1-for-9.7170 reverse stock split effected in connection with the IPO). Pursuant to the terms of the warrants, the Issuer withheld 1,065 shares of Common Stock from such shares to pay the exercise price in connection with the automatic net exercise of the SR One Fund I Aggregator Series D Warrants. SR One Fund I Aggregator now holds a total of 1,831,383 shares of Common Stock (the "SR One Fund I Aggregator Shares"). The working capital of SR One Fund I Aggregator is the source of the funds for the purchase of the SR One Fund I Aggregator Shares. No part of the purchase price of the SR One Fund I Aggregator Shares is represented by funds or other consideration borrowed or otherwise obtained for the purpose of acquiring, holding, trading or voting the SR One Fund I Aggregator Shares. Prior to the Closing, SR One Co-Invest IV purchased from the Issuer in a series of private transactions 1,151,580 shares of Series A Convertible Preferred Stock (the "SR One Co-Invest IV Series A Preferred Stock") for an aggregate purchase price of $4,999,999.14; and 2,374,981 shares of Series B Convertible Preferred Stock (the "SR One Co-Invest IV Series B Preferred Stock") for an aggregate purchase price of $15,000,000.00. Immediately prior to the Closing, the SR One Co-Invest IV Series A Preferred Stock automatically converted into 118,512 shares of Common Stock on a 1-for-9.7170 basis; and the SR One Co-Invest IV Series B Preferred Stock automatically converted into 255,823 shares of Common Stock on a 1-for-9.2837 basis. SR One Co-Invest IV now holds a total of 374,335 shares of Common Stock (the "SR One Co-Invest IV Shares"). The working capital of SR One Co-Invest IV is the source of the funds for the purchase of the SR One Co-Invest IV Shares. No part of the purchase price of the SR One Co-Invest IV Shares is represented by funds or other consideration borrowed or otherwise obtained for the purpose of acquiring, holding, trading or voting the SR One Co-Invest IV Shares. Prior to the Closing, SR One Co-Invest IV-A purchased from the Issuer in a series of private transactions 1,899,984 shares of Series B Convertible Preferred Stock (the "SR One Co-Invest IV-A Series B Preferred Stock") for an aggregate purchase price of $11,999,994.95; 200,000 shares of Series C Convertible Preferred Stock (the "SR One Co-Invest IV-A Series C Preferred Stock") for an aggregate purchase price of $1,000,000; and 1,614,650 shares of Series D Convertible Preferred Stock (the "SR One Co-Invest IV-A Series D Preferred Stock"), along with 484,395 warrants to purchase shares of Common Stock (the "SR One Co-Invest IV-A Series D Warrants"), for an aggregate purchase price of $2,429,999.82. Immediately prior to the Closing, the SR One Co-Invest IV-A Series B Preferred Stock automatically converted into 204,658 shares of Common Stock on a 1-for-9.2837 basis; the SR One Co-Invest IV-A Series C Preferred Stock automatically converted into 20,582 shares of Common Stock on a 1-for-9.7170 basis; the SR One Co-Invest IV-A Series D Preferred Stock automatically converted into 166,168 shares of Common Stock on a 1-for-9.7170 basis; and the SR One Co-Invest IV-A Series D Warrants were automatically exercised for 49,850 shares of Common Stock by their terms (as adjusted for the 1-for-9.7170 reverse stock split effected in connection with the IPO). Pursuant to the terms of the warrants, the Issuer withheld 277 shares of Common Stock from such shares to pay the exercise price in connection with the automatic net exercise of the SR One Co-Invest IV-A Series D Warrants. SR One Co-Invest IV-A now holds a total of 574,314 shares of Common Stock (the "SR One Co-Invest IV-A Shares"). The working capital of SR One Co-Invest IV-A is the source of the funds for the purchase of the SR One Co-Invest IV-A Shares. No part of the purchase price of the SR One Co-Invest IV-A Shares is represented by funds or other consideration borrowed or otherwise obtained for the purpose of acquiring, holding, trading or voting the SR One Co-Invest IV-A Shares. Prior to the Closing, AMZL purchased from the Issuer in a series of private transactions 4,500,000 shares of Series C Convertible Preferred Stock (the "AMZL Series C Preferred Stock") for an aggregate purchase price of $22,500,000.00; and 2,657,860 shares of Series D Convertible Preferred Stock (the "AMZL Series D Preferred Stock"), along with 764,312 warrants to purchase shares of Common Stock (the "AMZL Series D Warrants"), for an aggregate purchase price of $3,999,999.58. Immediately prior to the Closing, the AMZL Series C Preferred Stock automatically converted into 463,106 shares of Common Stock on a 1-for-9.7170 basis; the AMZL Series D Preferred Stock automatically converted into 273,527 shares of Common Stock on a 1-for-9.7170 basis, and the AMZL Series D Warrants were automatically exercised for 78,656 shares of Common Stock by their terms (as adjusted for the 1-for-9.7170 reverse stock split effected in connection with the IPO). Pursuant to the terms of the warrants, the Issuer withheld 438 shares of Common Stock from such shares to pay the exercise price in connection with the automatic net exercise of the AMZL Series D Warrants. AMZL now holds a total of 1,014,851 shares of Common Stock (the "AMZL Shares"). The working capital of AMZL is the source of the funds for the purchase of the AMZL Shares. No part of the purchase price of the AMZL Shares is represented by funds or other consideration borrowed or otherwise obtained for the purpose of acquiring, holding, trading or voting the AMZL Shares. Collectively, the Funds now hold a total of 3,794,883 shares of the Issuer's Common Stock (the "Fund Shares").

Item 4.

Purpose of Transaction

The Funds acquired their respective shares for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, the Funds and other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or (j) Any action similar to any of those enumerated above.

Item 5.

Interest in Securities of the Issuer

(a)

SR One Fund I Aggregator is the record owner of the SR One Fund I Aggregator Shares. As the general partner of SR One Fund I Aggregator, SR One Partners I may be deemed to beneficially own the SR One Fund I Aggregator Shares. As the general partner of SR One Partners I, SR One Capital Management may be deemed to beneficially own the SR One Fund I Aggregator Shares. As the managing member of SR One Capital Management, Dr. George may be deemed to beneficially own the SR One Fund I Aggregator Shares. SR One Co-Invest IV is the record owner of the SR One Co-Invest IV Shares. As the managing member of SR One Co-Invest IV, SR One Co-Invest IV Manager may be deemed to beneficially own the SR One Co-Invest IV Shares. As the managing member of SR One Co-Invest IV Manager, SR One Capital Management may be deemed to beneficially own the SR One Co-Invest IV Shares. As the managing member of SR One Capital Management, Dr. George may be deemed to beneficially own the SR One Co-Invest IV Shares. SR One Co-Invest IV-A is the record owner of the SR One Co-Invest IV-A Shares. As the managing member of SR One Co-Invest IV-A, SR One Co-Invest IV Manager may be deemed to beneficially own the SR One Co-Invest IV-A Shares. As the managing member of SR One Co-Invest IV Manager, SR One Capital Management may be deemed to beneficially own the SR One Co-Invest IV-A Shares. As the managing member of SR One Capital Management, Dr. George may be deemed to beneficially own the SR One Co-Invest IV-A Shares. AMZL is the record owner of the AMZL Shares. As the general partner of AMZL, SMA Partners may be deemed to beneficially own the AMZL Shares. As the general partner of SMA Partners, SR One Capital Management may be deemed to beneficially own the AMZL Shares. As the managing member of SR One Capital Management, Dr. George may be deemed to beneficially own the AMZL Shares. Each Reporting Person disclaims beneficial ownership of the Fund Shares other than those shares which such person owns of record. The percentage of outstanding shares of Common Stock which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person's cover sheet. Such percentage was calculated based on 47,174,156 shares of Common Stock reported by the Issuer to be outstanding as of May 11, 2026 (excluding the shares of Common Stock that the underwriters may purchase upon exercise of their option to purchase additional shares in full) as reported in the Issuer's prospectus dated May 7, 2026 filed with the SEC on May 8, 2026 pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended (the "Securities Act").

(b)

Regarding the number of shares as to which such person has: (i) sole power to vote or to direct the vote: See line 7 of cover sheets (ii) shared power to vote or to direct the vote: See line 8 of cover sheets (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets.

(c)

Except as set forth in Item 3 above, none of the Reporting Persons has effected any transaction in shares of Common Stock during the last 60 days.

(d)

No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, Common Stock beneficially owned by any of the Reporting Persons.

(e)

Not applicable.

Item 6.

Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

Each Fund is party to the Third Amended and Restated Investors' Rights Agreement with the Issuer and certain other stockholders (the "Investors' Rights Agreement"). The Investors' Rights Agreement grants the parties thereto, including the Funds, certain registration rights in respect of registrable securities. The registration of shares of the Issuer's Common Stock pursuant to the exercise of these registration rights will enable the holders thereof to sell such shares without restriction under the Securities Act when the applicable registration statement is declared effective. Under the Investors' Rights Agreement, the Issuer will pay all registration expenses and the holders will pay all underwriting discounts and selling commissions relating to the sale of their shares. The Investors' Rights Agreement also includes customary indemnification and procedural terms. These registration rights will expire no later than five years after the consummation of the IPO, or with respect to any particular holder, at such time that such holder can sell its shares under Rule 144 without limitation during any three-month period. The Investors' Rights Agreement provides that at any time beginning after the earlier of (i) five years after the date of the Investors' Rights Agreement and (ii) 180 days after May 11, 2026, the holders of a majority of the registrable securities then outstanding may request that the Issuer register all or a portion of their shares by filing a registration statement on Form S-1, provided that such request for registration covers at least 40% of the registrable securities then outstanding with an anticipated aggregate offering price of at least $10 million, net of applicable selling expenses. Once the Issuer is eligible to use a registration statement on Form S-3, the holders of at least 25% of the registrable securities then outstanding may request that the Issuer register their shares on Form S-3 if such holders hold registrable securities in an anticipated aggregate offering amount of at least $5 million, net of applicable selling expenses. Further, the Investors' Rights Agreement provides that in the event the Issuer proposes to register any of its securities under the Securities Act, either for its own account or for the account of other security holders, certain holders of registrable securities will be entitled to "piggyback" registration rights allowing such holders to include their shares in such registration, subject to certain marketing and other limitations. In addition, each Fund entered into a lock-up agreement in connection with the IPO whereby each Fund has agreed, subject to certain exceptions, that without the prior written consent of J.P. Morgan Securities LLC, TD Securities (USA) LLC and Cantor Fitzgerald & Co., that for a period of 180 days after May 7, 2026, it will not (i) offer, sell, contract to sell, pledge, grant any option, right or warrant to purchase, purchase any option or contract to sell, lend or otherwise transfer or dispose of any shares of Common Stock, or any options or warrants to purchase any shares of Common Stock, or any securities convertible into, exchangeable for or that represent the right to receive shares of Common Stock, including without limitation any such securities owned or later acquired, (ii) engage in any hedging or other transaction or arrangement (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward swap or any other derivative transaction or instrument, however described or defined) which is designed to or which reasonably could be expected to lead to or result in a sale, loan, pledge or other disposition (whether by the Fund or someone other than the Fund), or transfer of any of the economic consequences of ownership, in whole or in part, directly or indirectly, of any such securities, whether any such transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of Common Stock or other securities, in cash or otherwise, (iii) make any demand for or exercise any right with respect to the registration of any such securities or (iv) otherwise publicly announce any intention to engage in or cause any action, activity, transaction or arrangement described in clause (i), (ii) or (iii) above.

Item 7.

Material to be Filed as Exhibits.

Exhibit 1 - Agreement regarding filing of joint Schedule 13D. Exhibit 2 - Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

SR One Capital Management, LLC

Signature:	/s/ Sasha Keough
Name/Title:	Sasha Keough, as attorney-in-fact for Simeon George, M.D., Managing Member
Date:	05/18/2026

SR One Capital Fund I Aggregator, LP

Signature:	/s/ Sasha Keough
Name/Title:	Sasha Keough, as attorney-in-fact for Simeon George, M.D., Managing Member
Date:	05/18/2026

SR One Capital Partners I, LP

Signature:	/s/ Sasha Keough
Name/Title:	Sasha Keough, as attorney-in-fact for Simeon George, M.D., Managing Member
Date:	05/18/2026

SR One Co-Invest IV, LLC

Signature:	/s/ Sasha Keough
Name/Title:	Sasha Keough, as attorney-in-fact for Simeon George, M.D., Managing Member
Date:	05/18/2026

SR One Co-Invest IV-A, LLC

Signature:	/s/ Sasha Keough
Name/Title:	Sasha Keough, as attorney-in-fact for Simeon George, M.D., Managing Member
Date:	05/18/2026

SR One Co-Invest IV Manager, LLC

Signature:	/s/ Sasha Keough
Name/Title:	Sasha Keough, as attorney-in-fact for Simeon George, M.D., Managing Member
Date:	05/18/2026

AMZL, LP

Signature:	/s/ Sasha Keough
Name/Title:	Sasha Keough, as attorney-in-fact for Simeon George, M.D., Managing Member
Date:	05/18/2026

SR One Capital SMA Partners, LP

Signature:	/s/ Sasha Keough
Name/Title:	Sasha Keough, as attorney-in-fact for Simeon George, M.D., Managing Member
Date:	05/18/2026

Simeon George

Signature:	/s/ Sasha Keough
Name/Title:	Sasha Keough, as attorney-in-fact for Simeon George, M.D.
Date:	05/18/2026

Comments accompanying signature:

This Statement was executed by Sasha Keough on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 2.

Source: View Original Filing on SEC EDGAR

FAQ

How many Odyssey Therapeutics (ODTX) shares do the SR One funds beneficially own?

The SR One funds collectively beneficially own 3,794,883 shares of Odyssey Therapeutics common stock, equal to 8.0% of the company. This stake is spread across several SR One-managed vehicles, including SR One Fund I Aggregator, co-investment funds and AMZL.

What is the size and price of Odyssey Therapeutics (ODTX) IPO mentioned here?

Odyssey Therapeutics completed an initial public offering of 15,500,000 common shares at an IPO price of $18.00 per share. An additional 2,325,000 shares were available for underwriters’ over-allotment, which are excluded from the ownership percentage calculations in this disclosure.

What percentage of Odyssey Therapeutics (ODTX) does each SR One fund hold?

SR One Fund I Aggregator holds 1,831,383 shares (3.9%), SR One Co-Invest IV holds 374,335 shares (0.8%), SR One Co-Invest IV-A holds 574,314 shares (1.2%), and AMZL holds 1,014,851 shares (2.2%). SR One Capital Management and Dr. Simeon George may be deemed to control these holdings.

How many Odyssey Therapeutics (ODTX) shares were outstanding for the 8.0% calculation?

The 8.0% beneficial ownership figure is based on 47,174,156 Odyssey Therapeutics common shares outstanding as of May 11, 2026. This share count excludes any additional shares that underwriters may purchase through exercising their over-allotment option in the IPO.

What registration rights do the SR One funds have in Odyssey Therapeutics (ODTX)?

The SR One funds hold registration rights under a Third Amended and Restated Investors' Rights Agreement. They can request S-1 registration for at least 40% of registrable securities with a $10 million minimum, and S-3 registration for at least 25% with a $5 million minimum, plus piggyback rights.

How long are the SR One funds locked up from selling Odyssey Therapeutics (ODTX) shares?

Each fund agreed to a 180-day lock-up starting May 7, 2026. During this period, they generally cannot sell, hedge, or demand registration of Odyssey shares without prior written consent from the IPO underwriters J.P. Morgan Securities, TD Securities (USA) and Cantor Fitzgerald.

SR One funds disclose 8% Odyssey Therapeutics (ODTX) stake after IPO

Rhea-AI Filing Summary

Positive

Negative

Key Figures

Key Terms

FAQ

How many Odyssey Therapeutics (ODTX) shares do the SR One funds beneficially own?

What is the size and price of Odyssey Therapeutics (ODTX) IPO mentioned here?

What percentage of Odyssey Therapeutics (ODTX) does each SR One fund hold?

How many Odyssey Therapeutics (ODTX) shares were outstanding for the 8.0% calculation?

What registration rights do the SR One funds have in Odyssey Therapeutics (ODTX)?

How long are the SR One funds locked up from selling Odyssey Therapeutics (ODTX) shares?